GSK plc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? GSK plc trades at $50.56 (market cap $102.60B), while YieldMax TSLA Option Income Strategy ETF trades at $21.46. The key difference: GSK plc pays a 3.57% dividend while YieldMax TSLA Option Income Strategy ETF pays none, and GSK plc is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| GSK | TSLY | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $61.18 | $48.25 |
52-Week Low | $38.22 | $20.49 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
TSLY trades at $21.62, down 0.51% today, with a bearish technical outlook per moving averages and mixed oscillators. The ETF maintains high dividend distributions, with recent payouts ranging from $0.21 to $0.52 weekly, but faces capped upside risk due to its option income strategy structure. Recent news highlights concerns over missed Tesla rallies and volatility shifts, impacting sentiment.
Outlook is cautious due to structural limitations in capturing Tesla's gains, with risks including volatility dependency and competitive ETF strategies. The high yield attracts income seekers, but total return potential may be constrained if Tesla appreciates significantly, warranting careful risk assessment for equity-focused investors.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →